PMID: 28673352, 37374105 To view or add a comment, sign in From Insulin Resistance to Liver Damage:The Hidden Pathway of Fatty Liver Disease Fatty liver disease is not merely excess fat in the liver it is a metabolic outcome of insulin resistance
Mounjaro (tirzepatide) is covered for type 2 diabetes
Among fat loss peptides specifically, AOD 9604 stands out for having the most extensive human safety data from controlled trials
Keceli G, Gupta A, Sourdon J, Gabr R, Schr M, Dey S, Tocchetti CG, Stuber A, Agrimi J, Zhang Y, Leppo M, Steenbergen C, Lai S, Yanek LR, ORourke B, Gerstenblith G, Bottomley PA, Wang Y, Paolocci N, Weiss RG
While the pharmacokinetic reasoning for split dosing is sound, and while individual reports suggest it works well for many researchers, the formal evidence base does not yet exist
Nasal delivery eliminates several of these barriers simultaneously